Undisclosed RNA-targeted small molecule programs
Targeting traditionally undruggable RNA targets across multiple disease areas
DiscoveryActive
Key Facts
Indication
Targeting traditionally undruggable RNA targets across multiple disease areas
Phase
Discovery
Status
Active
Company
About Atomic AI
Atomic AI is a private, pre-clinical stage biotech founded in 2021, operating at the intersection of artificial intelligence and RNA therapeutics. The company has built a proprietary R&D platform that integrates its ATOM-1 deep learning model for RNA structure prediction with in-house wet-lab assays to accelerate drug discovery. By unlocking the 3D structure of RNA, Atomic AI aims to open a new frontier of drug targets for small molecules and RNA-based therapeutics, positioning itself in the rapidly growing field of computational drug discovery.
View full company profile